Only show
results from:

Sort results by:

Display preferences
393 results sorted by relevancy Results per page:
Accentia Biopharmaceuticals to Present at Rodman & Renshaw 10th Annual Healthcare Conference; Company Also Reports On NASDAQ Compliance Plan.
Business Wire; Oct 24, 2008; 700+ Words TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that...Bulletin Board or the Pink Sheets. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. (NASDAQ...
Accentia Biopharmaceuticals Reports Fiscal Third Quarter 2007 Financial Results.(Financial report)
Business Wire; Aug 14, 2007; 700+ Words ...Third Quarter of 2006 TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) has released the...Accentia's consolidated businesses. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical...
Accentia Biopharmaceuticals, Inc. Enters into a Definitive Agreement for a $25 Million Exchangeable Convertible Debenture Financing.
Business Wire; Oct 2, 2006; 700+ Words ...TAMPA, Fla. -- On September 29, 2006 Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) entered into a definitive...8-K filed October 2, 2006. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical...
Accentia Biopharmaceuticals Reports Fiscal First Quarter 2007 Financial Results.(Financial report)
Business Wire; Feb 15, 2007; 700+ Words ...Therapeutics Underway TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI; "Accentia") has...Accentia's consolidated businesses. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical...
Accentia Biopharmaceuticals Announces Pending Delisting from NASDAQ.
Business Wire; Nov 3, 2008; 700+ Words TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that...applicable regulatory authorities. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. (NASDAQ...
Accentia Biopharmaceuticals Reports Fiscal Third Quarter 2006 Financial Results; Accentia Reaches Significant Milestones, Including Commercial Launch of MD Turbo in Late June.
Business Wire; Aug 15, 2006; 700+ Words ...TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI...Biovest International, Inc. (OTCBB: BVTI...Hodgkin's lymphoma. Accentia has two business...2006, Accentia Biopharmaceuticals and its majority...
Accentia Biopharmaceuticals to Present at the Jefferies Second Annual Healthcare Conference.(Conference news)
Business Wire; Jun 23, 2008; 700+ Words TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that...at dwcalder@accentia.net. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. (Nasdaq...
Accentia Biopharmaceuticals' Development Partner Requests Meeting with FDA to Gain Clarification of Non-Approvable Letter for Emezine(R).(Correction Notice)
Business Wire; Mar 2, 2006; 700+ Words TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) has received notification...a subsidiary of BioDelivery. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical...
Accentia Biopharmaceuticals Makes Milestone Payment Based on Fast Tracked Pivotal Phase 3 Study with SinuNase for the Treatment of Chronic Sinusitis.
Business Wire; May 14, 2007; 700+ Words ...Prescription Antifungals TAMPA, Fla. -- Accentia Biopharmaceuticals Inc. (NASDAQ: ABPI; "Accentia") has...php, or call 212-686-4100. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. and its subsidiaries...
Accentia Biopharmaceuticals To Raise $ 8.2M in Equity Financing.
Business Wire; May 16, 2006; 700+ Words TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), on May 15, 2006...offer to buy shares or warrants. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical...
Accentia Biopharmaceuticals Reports Fiscal 2007 Year-End Results; Pivotal Phase III Results Pending for SinuNase(TM) and BiovaxID(TM).
Business Wire; Dec 28, 2007; 700+ Words TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that...operations, policies or practices. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceut
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI).
M2 Presswire; Apr 30, 2007; 700+ Words ...2007-Biotech News: Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI...date information on Accentia Biopharmaceuticals, Inc. are invited to sign...credit card needed! Accentia Biopharmaceuticals, Inc. reports the results...
Accentia Biopharmaceuticals Continues Nationwide Education Initiative to Promote Better Understanding of Chronic Sinusitis.
Business Wire; Mar 8, 2007; 700+ Words ...accentia.net/patients/trials_sinunase.php, or call 212-686-4100. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage "disruptive...
Accentia Biopharmaceuticals Receives NASDAQ Notice.
Business Wire; Sep 26, 2008; 700+ Words TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that...s common stock at this time. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. (Nasdaq...
Accentia Biopharmaceuticals, Inc. to Present at the Jefferies Healthcare Conference in New York City on Wednesday, June 27, 2007 at 9:40AM/ET.
Business Wire; Jun 26, 2007; 700+ Words ...at www.Accentia.net NEW YORK -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) will present at...website for 90 days. About Accentia Biopharmaceuticals Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively...
Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership.
Business Wire; Dec 21, 2006; 700+ Words ...of the physician investigators in the current Phase 3 trial are ENTs or allergists. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage "disruptive...
Accentia Biopharmaceuticals Licenses Targeted Technology For Treatment Of Chronic Rhinosinusitis (CRS): 37 Million Affected in the US and no Approved Pharmaceutical.
PR Newswire; Apr 13, 2004; 700+ Words ...bearing license, Accentia will file an IND on...Martin Baum, CEO of Accentia's specialty biopharmaceuticals business. "Moreover...Arikian, MD, CEO of Accentia's biopharmaceutical...exacerbations." Accentia, Inc., a Hopkins Capital...
Accentia Biopharmaceuticals, Inc. Updates Results of Nationwide Testing with CRSFungal Profile: The First Diagnostic Test Available for the Confirmation of Chronic Sinusitis.
Business Wire; Apr 24, 2007; 700+ Words ...Induced Inflammation TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI; "Accentia") reports...1046 or IMMCO 800-537-8378. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical...
Accentia Biopharmaceuticals Acquires Exclusive License for an Additional Late-Stage Respiratory Product.
Business Wire; Dec 6, 2005; 700+ Words TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that...New Drug Application (IND)." About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical...
Accentia Biopharmaceuticals Announces Reorganization Plan to Maximize Long-Term Shareholder Value, Fully Pay All Creditors and Continue Operations to Commercialize Its Drug Portfolio.
Business Wire; Nov 10, 2008; 700+ Words TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (Pink Sheets:ABPI) today announced...Real Player on your desk top. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. (Other OTC...
393 results: 1 | 2 | 3 | 4 | 5 | Next >>

Find articles, research, and archives